Literature DB >> 12505029

Travel and the spread of HIV-1 genetic variants.

Luc Perrin1, Laurent Kaiser, Sabine Yerly.   

Abstract

HIV-1 comprises three groups, the main (M group), O (outlier) and N (non-M, non-O). The M group, divided into 11 subtypes, is responsible for the global HIV-1 pandemic. Recombination between M subtypes has resulted in the generation of multiple circulating recombinant forms (CRFs) consisting of mosaic lineages. Most subtypes and CRFs are represented in Africa, whereas predominance of one or a few subtypes was reported initially elsewhere. This finding reflects the African origin of the epidemic. In western countries, where the B subtype is predominant, there is a steep increase in non B-subtypes and CRFs, while new recombinants emerge worldwide. Travellers contribute to the spread of HIV-1 genetic diversity worldwide, and in the developing world migration of rural populations and civil war are additional contributing factors. The spreading of HIV-1 variants has implications for diagnostic, treatment, and vaccine development.

Entities:  

Mesh:

Year:  2003        PMID: 12505029     DOI: 10.1016/s1473-3099(03)00484-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  42 in total

1.  Model-based inference of recombination hotspots in a highly variable oncogene [corrected].

Authors:  G Greenspan; D Geiger; F Gotch; M Bower; S Patterson; M Nelson; B Gazzard; J Stebbing
Journal:  J Mol Evol       Date:  2004-03       Impact factor: 2.395

2.  Rethinking global health training in North America.

Authors:  Rajesh Gupta; Peter Hotez
Journal:  MedGenMed       Date:  2006-08-24

Review 3.  Dilemma of concepts and strategies for the prevention of spread of HIV in relation to human behavior, law and human rights.

Authors:  Reinhard H Dennin; Michael Lafrenz; Arndt Sinn; Lan-juan Li
Journal:  J Zhejiang Univ Sci B       Date:  2011-07       Impact factor: 3.066

4.  Genomic Diversity of Human Immunodeficiency Viruses.

Authors:  R M Gupta; A K Sahni; J Jena; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-05-30

5.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

7.  Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Authors:  Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  Traveling young injection drug users at high risk for acquisition and transmission of viral infections.

Authors:  Judith A Hahn; Kimberly Page-Shafer; Jamye Ford; Alan Paciorek; Paula J Lum
Journal:  Drug Alcohol Depend       Date:  2007-11-05       Impact factor: 4.492

9.  TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Authors:  Hilde Azijn; Ilse Tirry; Johan Vingerhoets; Marie-Pierre de Béthune; Guenter Kraus; Katia Boven; Dirk Jochmans; Elke Van Craenenbroeck; Gaston Picchio; Laurence T Rimsky
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

10.  Man bites mosquito: understanding the contribution of human movement to vector-borne disease dynamics.

Authors:  Ben Adams; Durrell D Kapan
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.